<DOC>
	<DOCNO>NCT00637091</DOCNO>
	<brief_summary>The purpose study investigate response rate cetuximab plus irinotecan every 2 week patient harbor wild-type KRAS without detectable EGFR-expressing metastatic CRC failure irinotecan exploratory manner .</brief_summary>
	<brief_title>Efficacy Analysis Cetuximab Plus Irinotecan Patients With Wild-type KRAS Without Regard Epidermal Growth Factor Receptor ( EGFR ) Expressions</brief_title>
	<detailed_description>Twenty patient positive-EGFR result 20 patient negative-EGFR result accrue study . All patient wild-type KRAS .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Colorectal adenocarcinoma , Wild KRAS , 1875 yr Estimated life expectancy 3 month ECOG performance status 0 1 study entry Adequate bone marrow function Adequate liver function Documented progression within 3 month irinotecancontaining regimen firstline chemotherapy Immunohistochemical evidence presence absence EGFR expression PharmDx Kit Informed Consent Central nervous system ( CNS ) metastases prior radiation CNS metastases . Intestinal obstruction impend intestinal obstruction due peritoneal carcinomatosis Surgery ( exclude biopsy diagnosis ) 4 week prior inclusion study . Evidence gastrointestinal bleeding Exposure Cetuximab Prior administration monoclonal antibody , EGFR signal transduction inhibitor EGFRtargeted treatment KRAS mutant Status Patients serious toxicity previous irinotecanbased chemotherapy Other serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>